Surmodics, Inc. (SRDX)

NASDAQ: SRDX · Real-Time Price · USD
39.17
-0.02 (-0.05%)
Nov 20, 2024, 4:00 PM EST - Market closed
-0.05%
Market Cap 561.15M
Revenue (ttm) 126.08M
Net Income (ttm) -11.54M
Shares Out 14.33M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 81,300
Open 39.15
Previous Close 39.19
Day's Range 39.07 - 39.20
52-Week Range 25.17 - 42.44
Beta 1.20
Analysts Hold
Price Target 43.00 (+9.78%)
Earnings Date Nov 6, 2024

About SRDX

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Mar 4, 1998
Employees 376
Stock Exchange NASDAQ
Ticker Symbol SRDX
Full Company Profile

Financial Performance

In 2024, Surmodics's revenue was $126.08 million, a decrease of -4.91% compared to the previous year's $132.58 million. Losses were -$11.54 million, 651.4% more than in 2023.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for SRDX stock is "Hold." The 12-month stock price forecast is $43.0, which is an increase of 9.78% from the latest price.

Price Target
$43.0
(9.78% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported finan...

14 days ago - Business Wire

Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early ...

21 days ago - Business Wire

Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug Admi...

7 weeks ago - Business Wire

Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Earnings--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported f...

4 months ago - Business Wire

SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Surmodics, Inc. ...

4 months ago - Business Wire

Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing ...

5 months ago - Business Wire

SURMODICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

NEW ORLEANS, LA / ACCESSWIRE / May 30, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

6 months ago - Accesswire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.

NEW YORK , May 29, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Surmodics, Inc. (NASDAQ: SRDX) and its board of directors concerning the proposed acquis...

6 months ago - PRNewsWire

Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered ...

6 months ago - Business Wire

Surmodics, Inc. (SRDX) Q2 2024 Earnings Call Transcript

Surmodics, Inc. (NASDAQ:SRDX) Q2 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Gary Maharaj - President and Chief Executive Officer Timothy Arens - Chief Financial Officer...

7 months ago - Seeking Alpha

Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #PressRelease--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today report...

7 months ago - Business Wire

Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #EarningsCall--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announ...

7 months ago - Business Wire

Surmodics to Participate in Upcoming Investor Conferences in March and April

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that managem...

9 months ago - Business Wire

Surmodics, Inc (SRDX) Q1 2024 Earnings Call Transcript

Surmodics, Inc (SRDX) Q1 2024 Earnings Call Transcript

10 months ago - Seeking Alpha

Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...

10 months ago - Business Wire

Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced successful early clinical use of the co...

10 months ago - Business Wire

Surmodics to Host Virtual Annual Meeting of Shareholders

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting...

11 months ago - Business Wire

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first q...

11 months ago - Business Wire

Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that 24-mont...

1 year ago - Business Wire

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-mont...

1 year ago - Business Wire

Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that managem...

1 year ago - Business Wire

Surmodics, Inc. (SRDX) Q4 2023 Earnings Call Transcript

Surmodics, Inc. (SRDX) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...

1 year ago - Business Wire

Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Profess...

1 year ago - Business Wire

Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-mont...

1 year ago - Business Wire